Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Capmatinib in Metastatic Breast Cancer
NCT05243641Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib, capmatinib in breast cancer, inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2022; status: terminated.
02
Drugs
neratinibcapmatinib
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT05243641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243641.